First human test of mRNA shot targets deadly brain tumors

NCT ID NCT05938387

Completed Disease control Sponsor: CureVac Source: ClinicalTrials.gov ↗

Summary

This was an early-stage study to test the safety of a new mRNA vaccine, called CVGBM, for patients with a specific, aggressive type of brain tumor called glioblastoma. The study involved 37 adults who had their tumor surgically removed and completed standard radiation therapy. The main goal was to find a safe dose and check for side effects from a series of seven vaccine injections given over several weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

CHU de Liège

Liège, Belgium
Erasmusmc Cancer institute

Rotterdam, South Holland, Netherlands
Neurosurgical Clinic at the LMU Munich

München, Germany
Universitair Ziekenhuis Brussel - PPDS

Brussels, Belgium
Universitatsklinikum Leipzig

Leipzig, Saxony, Germany
University Clinic Heidelberg

Heidelberg, Baden-Wurttemberg, Germany
University Clinic Regensburg

Regensburg, Bavaria, Germany
University Hospital Essen

Essen, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn

Bonn, North Rhine-Westphalia, Germany
Universitätsklinikum Frankfurt

Frankfurt am Main, Hesse, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitätsklinikum Tübingen

Tübingen, Baden-Wurttemberg, Germany
Universitätsmedizin Mannheim

Mannheim, Baden-Wurttemberg, Germany

Conditions

Explore the condition pages connected to this study.

GLIOBLASTOMA